Skip to content
Bio Alps
FIND A HEALTH VALLEY ACTOR
Menu
Search
News
BioAlps news
BioAlps 20 years
Events
About
Mission
Organization
Members and Strategic Partners
BioAlps Awards
Media Center
BioAlps Event Formats
Business
Opportunities
Community
Membership Registration
The BioAlps Community
Cluster Expertise
Big data and bioinformatics
Biomaterials
Bioservices
Cardiovascular
Diagnostics
Drug delivery devices and development
Endocrinology and metabolism
Immunology
Medical technology
Neuroscience
Oncology
Orphan Drugs
The Health Valley
Business Enablers
Industrial network
Economic Promotion
International Markets
Innovation Enablers
Industrial Networks and Support Institutions
Technology Transfer Organisations
Incubators and Technoparks
Coaching
Financing
Startups and Success Stories
Research Institutions and Education
Universities and Academic Institutions
Research Centres
Research Networks
Education and Training
COVID-19 Key Players
News
« Back to News Listing
Posts navigation
← EPFL and UNIL discovery : How a mutated gene can lead to different forms of cancer
Progressive signaling changes in the olfactory nerve of Alzheimer’s disease patients →
ADC Therapeutics launches Phase I clinical trial
28.01.2019
Share this article
Facebook
X (Twitter)
Linkedin
The Swiss based startup,
ADC Therapeutics
, has dosed a solid tumor patient in its first Phase I clinical trial.
Read the
SBA’s
full
article
in English
Latest articles
17.12.2025
Altiscreen receives CHF 150,000 from Venture Kick
17.12.2025
Databaum and Lemna Bio Receive a Tech Seed Loan from FIT
16.12.2025
POSICS, Geneva Connection Technologies and Vectopia awarded FIF Grants
12.12.2025
Bio-Techne partners with Wyss Center Geneva
11.12.2025
DigeHealth secures CHF 1.25 million seed round to transform gastro-intestinal monitoring
